NCT02217137

Brief Summary

Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are chronic systemic autoimmune diseases that have been reported to affect the ocular surface of patients \[1,2\]. However, the nature of the disturbances of the ocular surface immunity and their relationship to systemic disease severity are poorly understood. This study aims to profile the ocular surface inflammation of RA and SLE patients by a., analysing levels of tear cytokine, and b., investigating conjunctival cells, and c. clinical imaging for conjunctival redness and tear stability. 20 consecutive RA patients and 20 consecutive SLE patients will be recruited from the Singapore General Hospital Rheumatology clinic. 20 age matched controls for SLE and another 20 age matched controls for RA will be recruited. All participants will undergo

  1. 1.Tear collection with Schirmer strips
  2. 2.EyePRIMTM (Opia Technologies) Impression Cytology Device for conjunctival sampling
  3. 3.Clinical ocular surface assessment with Oculus Keratograph 5M
  4. 4.Collection of blood via venipuncture (optional)
  5. 5.Retrieval of Clinical Information of participants

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2014

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

June 9, 2014

Completed
2 months until next milestone

First Posted

Study publicly available on registry

August 15, 2014

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2015

Completed
Last Updated

November 18, 2015

Status Verified

June 1, 2014

Enrollment Period

1.3 years

First QC Date

June 9, 2014

Last Update Submit

November 16, 2015

Conditions

Keywords

Dry EyeRheumatoid ArthritisSystemic Lupus ErythematosusTear cytokines and immune response

Outcome Measures

Primary Outcomes (1)

  • Profile tear cytokines

    the inflammatory cytokines concentration

    1 day

Secondary Outcomes (1)

  • Profile immune response

    1 day

Eligibility Criteria

Age21 Years - 99 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Rheumatoid Arthriris, Systemic Lupus Erythematosus and healthy normal volunteers will be recruited.

You may qualify if:

  • Clinically diagnosed with Rheumatoid Arthritis or Systemic Lupus Erythematosus

You may not qualify if:

  • Known history of thyroid disorders (diagnosed by physician).
  • No ocular surgery within the last 3 months and LASIK within 1 year.
  • Ocular surface diseases such as pterygium, or obvious lid/orbital disease with lagophthalmos.
  • Any other specified reason as determined by clinical investigator.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Singapore Eye Research Institute

Singapore, Singapore, 168751, Singapore

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Tear samples will be collected from the schimers strips for protein analysis

MeSH Terms

Conditions

Dry Eye SyndromesArthritis, RheumatoidLupus Erythematosus, Systemic

Condition Hierarchy (Ancestors)

Lacrimal Apparatus DiseasesEye DiseasesArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinician-Scientist, Senior Consultant

Study Record Dates

First Submitted

June 9, 2014

First Posted

August 15, 2014

Study Start

June 1, 2014

Primary Completion

September 1, 2015

Study Completion

September 1, 2015

Last Updated

November 18, 2015

Record last verified: 2014-06

Locations